Stock Upgrades Today Show Top Picks

 TopRated
 
  TopRated
 
Follow  Message
 
 
 
TopRatedStocks uncovering top-rated companies. Providing quick insights and recommendations, they help investors discover high-potential stocks based on robust metrics.
 

•  10 Dec 2025
 

•   ALAB  
   
  +5.55%
•   ALLR  
   
  -0.86%
•   BTSG  
   
  +1.90%
•   BWMN  
   
  +0.36%
•   CGEM  
   
  -1.12%

$A Goldman Sachs has initiated coverage of Agilent Technologies with a Buy recommendation suggesting an upside potential of 19.71%. The strong position in life sciences and analytical instruments provides solid near-term growth opportunities for investors.

$ALAB Northland Capital Markets maintains an Outperform rating on Astera Labs with a projected upside of 17.19%. Its exposure to semiconductors and data center connectivity positions the company to benefit from increasing AI and high-performance computing demand.

$ALLR Ascendiant Capital continues to support Allarity Therapeutics with a Buy rating forecasting a remarkable 713.36% upside. The biotechs innovative pipeline and clinical potential make it a high-risk high-reward opportunity for aggressive investors.

$ASUR Barrington Research keeps an Outperform rating on Asure Software projecting 65.89% upside. The growing enterprise software and cloud adoption trends underpin strong growth prospects.

$BTSG B of A Securities retains a Buy rating on BrightSpring Health Services with a 19.03% upside. Steady demand for healthcare services offers near-term revenue stability and growth.

$BWMN Roth Capital maintains a Buy rating on Bowman Consulting Group with a 45.18% upside. Infrastructure and engineering project growth supports the companys expansion potential.

$CGEM Wedbush keeps an Outperform rating on Cullinan Therapeutics with 120.47% upside, reflecting strong confidence in the biotech pipeline and upcoming clinical catalysts.

$CI TD Cowen reaffirms a Buy rating on Cigna Group with a 25.5% upside and highlights it as a Best Ideas pick for 2026. The healthcare insurance sector remains resilient and provides solid growth visibility.

$NVO Berenberg Bank reaffirms Buy on Novo Nordisk projecting 29% upside driven by diabetes and obesity treatment trends that support sustained demand.

$OCUL Chardan Capital maintains Buy on Ocular Therapeutix with 41.4% upside, backed by innovative therapies in ophthalmology that could drive near-term growth.

$OSTX D Boral Capital maintains Buy on OS Therapies with an exceptional 563.52% upside, fueled by breakthrough therapies and high potential clinical developments.

$PHR Needham Citigroup and Canaccord maintain Buy on Phreesia with 71.35% upside, supported by expanding healthcare technology adoption.

$RAPP HC Wainwright maintains Buy on Rapport Therapeutics with 74.17% upside reflecting confidence in its clinical pipeline and development milestones.

$RCL Goldman Sachs maintains Buy on Royal Caribbean with 33.8% upside. Cruise industry recovery and travel demand growth support a strong near-term rebound.

$SNTI Chardan Capital maintains Buy on Senti Biosciences with 380.13% upside, making it one of the most compelling high-risk, high-reward biotech opportunities.

$SRAD UBS maintains Buy on Sportradar Group with 44.69% upside benefiting from the expanding sports data and betting markets.

$SW Argus Research maintains Buy on Smurfit Westrock with 50.58% upside reflecting solid demand in packaging and recycling solutions.

$TDUP Telsey Advisory maintains Outperform on ThredUp with 50.18% upside, driven by growing online resale and e-commerce trends.

$TE Alliance Global Partners initiates coverage on T1 Energy with Buy and 18.6% upside backed by energy sector tailwinds.

$VNCE Small Cap Consumer Research maintains Buy on Vince Holding with 35.47% upside supported by niche consumer brand growth and strong seasonal demand.

View All Headlines